Skip to main content

Catalyst Calendar

Fri, Jul 24, 2026

1 updates

8:51 AM

Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

sanofi.com

Fri, Jul 10, 2026

1 updates

10:27 AM

Sanofi’s subcutaneous Sarclisa Escena approved in the US as first anticancer treatment administered via on-body injector

sanofi.com

Fri, Jun 12, 2026

1 updates

7:29 PM

Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

sanofi.com

Thu, May 28, 2026

1 updates

1:00 AM

Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

sanofi.com

Mon, May 18, 2026

1 updates

3:47 PM

ATS: phase 2 data demonstrate the superiority of efdoralprin alfa over a standard-of-care augmentation therapy in achieving higher fAAT levels in AATD

Presentation / Abstract • Phase 2ATS presentation Mon, May 18, 2026sanofi.com